about
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideDoes an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphomaA phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Spotlight on lenalidomide in relapsed or refractory multiple myeloma.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.Molecular targeted approaches for treatment of pancreatic cancer.Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELALenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.Structural basis of thalidomide enantiomer binding to cereblon.IMiD compounds affect CD34 cell fate and maturation via CRBN-induced IKZF1 degradation
P2860
Q24614147-26F05BD9-CDAA-425C-8C46-822824CD174CQ26768699-7F36D759-215A-43D9-B09E-B401FDE05130Q28649793-D61BF875-982B-446E-B505-13D71CB44F94Q33397302-BFBF03E1-7457-4FB1-9FE6-70CB9636A619Q34028642-FA423BCF-A35F-4853-ACD5-463BA7BCDB1BQ34210005-9A9FA3C5-D9AE-44F4-A9FC-87DD9BF5D034Q36132803-35216133-BF62-4627-A4F9-B28FD6574828Q36174910-5A05DAA5-5685-4DB8-A6F1-D48899810374Q36366982-FCD06525-57FF-46E1-8979-56281C0C06C9Q36848023-BC627F0F-BA42-4AD1-B95F-17ECD2C6898BQ37858523-C5B069DA-C00C-4694-BA25-A0277DF70D94Q37866341-6D4B0ED3-84BC-4937-8EAB-A598F1C0B89EQ38450335-1DF9CC71-740B-4321-97E7-EF254C3E0ED5Q41878942-00A01E60-B232-44C3-AA8C-EC1C2682E81DQ48191012-EFCC7A7E-184B-45FD-8C4D-DA3B266B83A2Q58299695-C778162C-307D-4E4B-8A2C-4B388BBFEBF0
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Recent advances of IMiDs in cancer therapy.
@ast
Recent advances of IMiDs in cancer therapy.
@en
Recent advances of IMiDs in cancer therapy.
@nl
type
label
Recent advances of IMiDs in cancer therapy.
@ast
Recent advances of IMiDs in cancer therapy.
@en
Recent advances of IMiDs in cancer therapy.
@nl
prefLabel
Recent advances of IMiDs in cancer therapy.
@ast
Recent advances of IMiDs in cancer therapy.
@en
Recent advances of IMiDs in cancer therapy.
@nl
P2093
P1476
Recent advances of IMiDs in cancer therapy.
@en
P2093
Navkiranjit Gill
Shirong Li
Suzanne Lentzsch
P304
P356
10.1097/CCO.0B013E32833D752C
P577
2010-11-01T00:00:00Z